Parallel Advisors’s Taysha Gene Therapies TSHA Stock Holding History

Parallel Advisors’s Portfolio TSHA Stock Details TSHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.91K	Sell	280 -6	-2%	-$36	﹤0.01%	3528
2026 Q1	$1.28K	Buy	286 +6	+2%	+$28	﹤0.01%	3490
2025 Q4	$1.54K	Hold	280	–	–	﹤0.01%	3204
2025 Q3	$916	Hold	280	–	–	﹤0.01%	3241
2025 Q2	$647	Hold	280	–	–	﹤0.01%	3271
2025 Q1	$389	Hold	280	–	–	﹤0.01%	3277
2024 Q4	$484	Hold	280	–	–	﹤0.01%	3228
2024 Q3	$563	Hold	280	–	–	﹤0.01%	3163
2024 Q2	$627	Buy	+280	New	+$815	﹤0.01%	3051
2022 Q1	–	Sell	-45	Closed	-$1K	–	3277
2021 Q4	$1K	Buy	+45	New	+$679	﹤0.01%	2971

Other funds holding TSHA

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Parallel Advisors's TSHA Position: Q2 2026 in Review

Parallel Advisors reduced its Taysha Gene Therapies (TSHA) stake by 2.1% in Q2 2026, selling an estimated $36 and leaving 280 shares worth $1.91K. The position accounts for ﹤0.01% of the portfolio, ranked #3528.

Parallel Advisors first reported a position in TSHA in Q4 2021 and has held it in 10 quarters since. 208 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

Parallel Advisors held 280 shares of Taysha Gene Therapies worth $1.91K as of Q2 2026.
Parallel Advisors sold 6 Taysha Gene Therapies shares in Q2 2026, an estimated $36.
Taysha Gene Therapies made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #3528 holding.
Parallel Advisors first reported a position in Taysha Gene Therapies in Q4 2021 and has held it in 10 quarters since.
208 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.